Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Cash & Current Investments (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of Cash & Current Investments data on record, last reported at $202.9 million in Q3 2021.

  • For Q3 2021, Cash & Current Investments rose 56.77% year-over-year to $202.9 million; the TTM value through Sep 2021 reached $202.9 million, up 56.77%, while the annual FY2020 figure was $242.2 million, 547.15% up from the prior year.
  • Cash & Current Investments reached $202.9 million in Q3 2021 per COGT's latest filing, down from $218.1 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $242.2 million in Q4 2020 and bottomed at $484000.0 in Q3 2019.
  • Average Cash & Current Investments over 4 years is $105.8 million, with a median of $80.4 million recorded in 2018.
  • Peak YoY movement for Cash & Current Investments: crashed 52.38% in 2019, then surged 47279.67% in 2021.
  • A 4-year view of Cash & Current Investments shows it stood at $78.6 million in 2018, then plummeted by 52.38% to $37.4 million in 2019, then skyrocketed by 547.15% to $242.2 million in 2020, then dropped by 16.23% to $202.9 million in 2021.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $202.9 million in Q3 2021, $218.1 million in Q2 2021, and $230.7 million in Q1 2021.